Truncated forms of iga protease, fusion proteins comprising a truncated form of iga protease and uses thereof
AssigneesPeking University First Hospital, Shanghai Alezyme Pharmaceuticals Ltd.
InventorsJicheng LV, Hong ZHANG, Chutian SHU
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a truncated form of IgA protease, a fusion protein comprising a truncated form of IgA protease (e.g., a fusion protein comprising a truncated form of IgA protease and Fc) and uses thereof in treating diseases associated with IgA deposition (e.g., IgA nephropathy).
Claims32
An isolated truncated form of IgA protease comprising a non-natural truncated fragment of a wild-type IgA protease obtained from or derived from Clostridium ramosum or having at least 70% sequence identity to the non-natural truncated fragment.
3-4. (canceled)
(canceled)
9-10. (canceled)
(canceled)
(canceled)
17-23. (canceled)
(canceled)
28-51. (canceled)
(canceled)
56-60. (canceled)
A method of treating or preventing a disease associated with IgA deposition, comprising administering to a subject in need thereof an IgA protease or a truncated form thereof, a fusion protein comprising the IgA protease or a truncated form thereof, or a pharmaceutical composition comprising the IgA protease or a truncated form thereof, wherein an amino acid sequence of the IgA protease is selected from the group consisting of SEQ ID NO:
- 61, SEQ ID NO:
- 62, SEQ ID NO:
- 63, SEQ ID NO:
- 64, SEQ ID NO:
- 65, SEQ ID NO:
- 66, SEQ ID NO:
- 67, SEQ ID NO:
- 68, SEQ ID NO:
- 69, SEQ ID NO:
- 70, SEQ ID NO:
- 71, SEQ ID NO:
- 72, SEQ ID NO:
- 73, SEQ ID NO:
- 74, SEQ ID NO:
- 75, SEQ ID NO:
- 76 or a combination thereof.
65-66. (canceled)
(canceled)
Dependencies are inferred from the claim text.